Rufinamide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Rufinamide

Examples of brand names: Inovelon [EU/DE]

ATC code: N03AF03

Main use (for orientation): Lennox–Gastaut syndrome

Documented research summary

An earlier open-label CBD programme showed increased rufinamide concentrations; a later expanded analysis did not (n=28, p=0.9952). Not independent replications; non-significance does not exclude an effect. A CYP3A risk framework is unsuitable for the principal non-CYP-dependent hydrolysis pathway.

Uncertainties and limitations

BANZEL oral tablets/suspension, label-confirmed mg-for-mg bioequivalence; no blanket CYP3A-substrate mechanism.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

CL20 methods, Table 2 and discussion read in the locally available PMC full text; initial web PMC access encountered a CAPTCHA.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0071

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.9952.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: n=28.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context / limitations of CL20; a lack of statistical significance does not establish equivalence.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

CBD – clinical signals

Finding ID: B0075

Type of result: Positive finding / indication

Observation: Concentration increase associated with CBD dose.

Mechanism: Mechanism uncertain

Study type: Open-label observational study

Context studied: 81 overall; children/adults.

Clinical interpretation: Unclear

Limitations and uncertainties: Consider CL20 as a later analysis; not an independent replication.

Original sources for this finding: Interactions between cannabidiol and commonly used antiepileptic drugs [CL21]

References and access status

[V2_LABEL_D0443] BANZEL (RUFINAMIDE) TABLET, FILM COATED BANZEL (RUFINAMIDE) SUSPENSION [EISAI INC.]

Original source / bibliographic reference

Authors: Eisai Inc.

Year: 2022

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CL21] Interactions between cannabidiol and commonly used antiepileptic drugs

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Liu Y; Szaflarski JP; UAB CBD Program

Year: 2017

Source type: Open-label observational study

DOI: 10.1111/epi.13852

PMID: 28782097

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[BMED31382177] Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.

Original source / bibliographic reference

Authors: Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP, Szaflarski JP, UAB CBD Program.

Year: 2019

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.yebeh.2019.07.008

PMID: 31382177

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility